North Star Investment Management Corp. Increases Stock Holdings in Embecta Corp. $EMBC

North Star Investment Management Corp. raised its position in Embecta Corp. (NASDAQ:EMBC) by 305,000.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,020 shares of the company’s stock after acquiring an additional 61,000 shares during the quarter. North Star Investment Management Corp. owned approximately 0.10% of Embecta worth $861,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in EMBC. Tower Research Capital LLC TRC grew its holdings in shares of Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after purchasing an additional 6,224 shares in the last quarter. CWM LLC boosted its position in Embecta by 16.0% in the 2nd quarter. CWM LLC now owns 8,080 shares of the company’s stock valued at $78,000 after buying an additional 1,115 shares during the period. Humankind Investments LLC acquired a new position in shares of Embecta in the second quarter worth $111,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Embecta by 7.9% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 15,005 shares of the company’s stock worth $145,000 after acquiring an additional 1,093 shares during the period. Finally, Quantbot Technologies LP purchased a new stake in shares of Embecta during the second quarter worth $147,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Stock Performance

EMBC opened at $12.39 on Wednesday. Embecta Corp. has a one year low of $9.20 and a one year high of $21.10. The company has a market cap of $733.61 million, a P/E ratio of 7.60 and a beta of 1.11. The business’s 50-day simple moving average is $12.74 and its 200-day simple moving average is $12.74.

Embecta (NASDAQ:EMBC) last announced its quarterly earnings results on Tuesday, November 25th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.04. Embecta had a negative return on equity of 24.62% and a net margin of 8.83%.The firm had revenue of $263.30 million during the quarter, compared to the consensus estimate of $265.66 million. During the same period in the prior year, the company posted $0.45 earnings per share. The firm’s quarterly revenue was down 7.7% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts predict that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 18th. Investors of record on Friday, December 5th were paid a dividend of $0.15 per share. This represents a $0.60 annualized dividend and a yield of 4.8%. The ex-dividend date was Friday, December 5th. Embecta’s dividend payout ratio (DPR) is currently 36.81%.

Analyst Ratings Changes

Several research analysts recently commented on the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Embecta in a research note on Wednesday, October 8th. Wall Street Zen raised Embecta from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Zacks Research lowered shares of Embecta from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 7th. Finally, BTIG Research reiterated a “buy” rating on shares of Embecta in a research note on Tuesday, November 25th. One analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Embecta currently has an average rating of “Hold” and a consensus target price of $18.50.

About Embecta

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.